Gene Therapy for Infectious Diseases
Inquiry
Advances in gene therapy research have provided effective solutions for infectious disease gene therapy. CD Formulation has extensive research and service experience in the development of gene therapy formulations, particularly for infectious disease technical support. We are constantly optimizing and updating our technology systems to best meet the research needs of our clients' projects.
Advantages of Gene Therapy for Infectious Diseases
- Addressing the problem at the source. Infectious disease gene therapy plays can target the root cause of the disease and address infectious diseases at the source.
- Strong targeting. Gene therapy for infectious diseases usually has a clear target point and stronger specificity, which can realize precise treatment and better therapeutic effect and can effectively reduce the damage to normal cells and improve the safety and effectiveness of treatment.
- Wide range of indications. The research progress of gene therapy has brought new means and methods for some refractory infectious diseases that are currently untreatable or with poor efficacy.
Main Applications of Gene Therapy for Infectious Diseases
HIV gene therapy
There have been major advances in gene therapy research for this disease in the following areas.
CRISPR gene editing. Delivery of CRISPR-Cas9 via AAV targets the cleavage of integrated HIV proviruses and significantly reduces the viral reservoir. Clinical trials have shown delayed viral rebound and reduced viral reservoirs in some patients after drug discontinuation.
CAR-T immunotherapy. Enhances the immune response by modifying a patient's T-cells to specifically recognize and remove HIV-infected cells.
We offer the following services for HIV gene therapy agent development.
- Viral vector optimization. We design highly targeted gene delivery systems based on lentiviral, AAV, and other vectors.
- Drug-resistant strain solutions. Develop multiple sgRNA editing strategies to cover highly mutated regions of HIV and reduce the risk of off-targeting.
HPV gene therapy
The main advances in gene therapy research for this disease are as follows.
Prophylactic vaccines. Genetically engineered modified HPV vaccines have been widely used to prevent high rates of infection.
Therapeutic gene editing. CRISPR is used to target and cut HPV oncogenes (e.g., E6/E7) to block tumor progression. Preclinical studies have shown that this technology significantly inhibits cervical cancer cell proliferation.
We offer the following services for HIV gene therapy formulation development.
- Rapid assay development. CRISPR-Cas12a-based molecular diagnostic tools for highly sensitive detection of HPV typing.
- Therapeutic vector development. Design tissue-specific AAVs to target cervical epithelial cells for delivery of therapeutic genes.
HBV gene therapy
HBV cccDNA is latent in hepatocytes for a long time and cannot be cleared by existing drugs. Gene therapy research has led to alternative solutions for this disease.
CRISPR targets cccDNA. cccDNA cleavage by Cas9 significantly reduces viral load. Preclinical models show that a single treatment can reduce the viral reservoir by more than 90%.
AAV therapy. Such as AAV vectors, which inhibit replication by silencing viral mRNA, show good potential for application.
We offer the following services for HBV gene therapy agent development.
- cccDNA detection technology. We provide non-invasive testing programs such as microdroplet digital PCR (ddPCR) to dynamically assess efficacy.
- Liver-targeted delivery systems. Develop GalNAc-modified siRNA or CRISPR complexes to enhance liver specificity.
Our Capabilities of Gene Therapy for Infectious Diseases
- We have an advanced technology platform for the development of gene therapy formulations to provide comprehensive solutions for the treatment of infectious diseases.
- In gene therapy formulation development, we can provide personalized drug development services according to customer needs, covering the entire process from early research to preclinical.
- We have accumulated rich R&D experience in gene therapy research for infectious diseases and are able to provide reliable research solutions based on the characteristics of customer projects.
Explore Our Gene Therapy Formulation Development for Infectious Diseases
Gene Editing Technology
We provide gene editing technology support, including CRISPR-Cas9 technology, which can be widely used for the precise editing of genomes to efficiently delete, insert, or replace specific genes. In addition, we utilize TALEN technology to edit target genes by utilizing specific nucleic acid binding proteins, which are applicable to a wide range of cell types.
Vector System Development
We help researchers develop advanced drug delivery vectors, including the development of viral vectors such as adenovirus, lentivirus, and adeno-associated virus (AAV). In addition, we offer lipid nanoparticles (LNPs) and polymer vectors, plasmids, and other non-viral vectors with improved safety and biocompatibility.
CD Formulation is committed to helping our customers shorten the progress of gene therapy formulation development. We provide comprehensive technical support and solutions for gene therapy research, significantly reducing our customers' research and development costs and accelerating the gene therapy formulation development process. If you are interested in us, please feel free to contact us.
Related Services
